Inmune Bio Appoints Dr. David M. Reifman as CMO
Ticker: INMB · Form: 8-K · Filed: Oct 25, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Oct 25, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
Inmune Bio just hired a new CMO, Dr. David M. Reifman. Big move for their clinical strategy.
AI Summary
On October 24, 2024, Inmune Bio, Inc. filed an 8-K report detailing the appointment of Dr. David M. Reifman as Chief Medical Officer. Dr. Reifman brings extensive experience in clinical development and regulatory affairs, particularly in the oncology and immunology fields. This appointment is expected to bolster the company's leadership as it advances its therapeutic candidates.
Why It Matters
The appointment of a new Chief Medical Officer with relevant experience can signal a strategic shift or acceleration in the company's drug development pipeline, potentially impacting future clinical trial progress and regulatory approvals.
Risk Assessment
Risk Level: medium — The appointment of a new executive can introduce new strategic directions or integration challenges, but the filing itself does not contain immediate financial risks.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- Dr. David M. Reifman (person) — Appointed Chief Medical Officer
- Nevada (jurisdiction) — State of incorporation
- Boca Raton, Florida (location) — Principal Executive Offices
FAQ
What is the effective date of Dr. David M. Reifman's appointment as Chief Medical Officer?
The filing does not explicitly state an effective date for Dr. Reifman's appointment, but it was reported on October 24, 2024.
What is Inmune Bio, Inc.'s principal executive office address?
Inmune Bio, Inc.'s principal executive offices are located at 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432.
What is Inmune Bio, Inc.'s IRS Employer Identification Number?
Inmune Bio, Inc.'s IRS Employer Identification Number is 47-5205835.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Inmune Bio, Inc.'s Standard Industrial Classification code?
Inmune Bio, Inc.'s Standard Industrial Classification code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 456 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-10-25 16:00:27
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea0218672-8k_inmune.htm (8-K) — 35KB
- ea021867201ex99-1_inmune.htm (EX-99.1) — 16KB
- 0001213900-24-090766.txt ( ) — 227KB
- inmb-20241024.xsd (EX-101.SCH) — 3KB
- inmb-20241024_lab.xml (EX-101.LAB) — 33KB
- inmb-20241024_pre.xml (EX-101.PRE) — 22KB
- ea0218672-8k_inmune_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: October 25, 2024 By: /s/ David Moss Name: David Moss Title: Chief Financial Officer 2